## Patrik Nasr

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3797900/publications.pdf

Version: 2024-02-01

414303 361296 5,448 33 20 32 citations h-index g-index papers 34 34 34 5716 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care. Scandinavian Journal of Gastroenterology, 2022, 57, 60-69.	0.6	3
2	Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. Journal of Hepatology, 2022, 76, 1013-1020.	1.8	66
3	Repeated measurements of nonâ€invasive fibrosis tests to monitor the progression of nonâ€alcoholic fatty liver disease: A longâ€term followâ€up study. Liver International, 2022, 42, 1545-1556.	1.9	6
4	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. Hormones, 2022, 21, 349-368.	0.9	12
5	Hepatic patatinâ€like phospholipase domainâ€containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans. Hepatology Communications, 2022, 6, 2689-2701.	2.0	5
6	Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 2021, 115, 154439.	1.5	41
7	Serum levels of endotrophin are associated with nonalcoholic steatohepatitis. Scandinavian Journal of Gastroenterology, 2021, 56, 437-442.	0.6	4
8	A Dynamic Aspartateâ€toâ€Alanine Aminotransferase Ratio Provides Valid Predictions of Incident Severe Liver Disease. Hepatology Communications, 2021, 5, 1021-1035.	2.0	23
9	Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction. JHEP Reports, 2021, 3, 100218.	2.6	26
10	Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol. BMC Gastroenterology, $2021, 21, 180$ .	0.8	5
11	Low hepatic manganese concentrations in patients with hepatic steatosis – A cohort study of copper, iron and manganese in liver biopsies. Journal of Trace Elements in Medicine and Biology, 2021, 67, 126772.	1.5	15
12	Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls. Clinical Gastroenterology and Hepatology, 2020, 18, 1592-1599.e8.	2.4	21
13	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemporary Clinical Trials, 2020, 98, 106175.	0.8	71
14	Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography. Scandinavian Journal of Gastroenterology, 2020, 55, 848-859.	0.6	15
15	Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2020, 111, 154183.	1.5	39
16	The amount of liver fat predicts mortality and development of type 2 diabetes in nonâ€alcoholic fatty liver disease. Liver International, 2020, 40, 1069-1078.	1.9	31
17	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology, 2020, 158, 1611-1625.e12.	0.6	575
18	Modifiers of Liver-Related Manifestation in the Course of NAFLD. Current Pharmaceutical Design, 2020, 26, 1062-1078.	0.9	8

#	Article	IF	Citations
19	Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1148-1156.e4.	2.4	71
20	Cardiovascular risk factors in nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 197-204.	1.9	75
21	Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A longâ€term followâ€up study. Hepatology Communications, 2018, 2, 48-57.	2.0	200
22	Natural history of nonalcoholic fatty liver disease: A prospective followâ€up study with serial biopsies. Hepatology Communications, 2018, 2, 199-210.	2.0	102
23	Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and metaâ€analysis. Hepatology, 2017, 65, 1557-1565.	3.6	1,294
24	Using a 3% Proton Density Fat Fraction as a Cut-Off Value Increases Sensitivity of Detection of Hepatic Steatosis, Based on Results From Histopathology Analysis. Gastroenterology, 2017, 153, 53-55.e7.	0.6	51
25	Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. Journal of Hepatology, 2017, 67, 1265-1273.	1.8	730
26	SAF score and mortality in NAFLD after up to 41 years of follow-up. Scandinavian Journal of Gastroenterology, 2017, 52, 87-91.	0.6	32
27	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2017, 52, 159-165.	0.6	60
28	Automated quantification of steatosis: agreement with stereological point counting. Diagnostic Pathology, 2017, 12, 80.	0.9	15
29	Natural History of NAFLD/NASH. Current Hepatology Reports, 2017, 16, 391-397.	0.4	102
30	Reply. Hepatology, 2016, 64, 310-311.	3.6	0
31	Elevated serum ferritin is associated with increased mortality in nonâ€alcoholic fatty liver disease after 16 years of followâ€ap. Liver International, 2016, 36, 1688-1695.	1.9	54
32	Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2016, 51, 1126-1132.	0.6	13
33	Fibrosis stage is the strongest predictor for diseaseâ€specific mortality in NAFLD after up to 33 years of followâ€up. Hepatology, 2015, 61, 1547-1554.	3.6	1,683